MedTrace Logo

Compassionate Use of Sodium Stibogluconate (Pentostam) for Cutaneous and Mucocutaneous New World Leishmaniasis

NCT00508963 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2023-12-27

No results posted yet for this study

Summary

Patients with biopsy proven new world cutaneous or mucocutaneous leishmaniasis will be treated with sodium stibogluconate (Pentostam).

Conditions

  • Leishmaniasis, Cutaneous
  • Leishmaniasis, Mucocutaneous

Interventions

DRUG

sodium stibogluconate (Pentostam)

20 mg/kg IV every day for 20 or 28 days

Sponsors & Collaborators

Principal Investigators

  • Brian Schwartz, MD · University of CA at San Francisco

  • Kanade Shinkai, MD · University of CA at San Francisco

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00508963 on ClinicalTrials.gov